Oral cancer treatment and reconstruction | Oral Cancer News
Links shared publicly online about this topic.
- 1,044total visits
Oral cancer treatment and reconstruction | Oral Cancer News
View full resource at oralcancernews.org
Most Recently Shared on July 5, 2010 at 7:24 pm By:
RT @Oralcancerfnd Oral cancer treatment and reconstruction http://bit.ly/97IxEC
Clovis Oncology Announces Enrollment of First Patient in First Human Study of Oral EGFR Mutant-Selective Inhibitor CO-1686 - Yahoo! News
news.yahoo.com — “From Yahoo! News: Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer (NSCLC).” View full resource at news.yahoo.com
Most Recently Shared on March 28, 2012 at 11:04 am By:
Clovis Oncology Announces Enrollment of First Patient in First Human Study of Oral EGFR Mutant-Selective Inhibit... http://t.co/48JzhFAO
Common medicines may cut cancer drug potency | Fox News
foxnews.com — “Many patients taking a widely prescribed class of oral cancer drugs are also using a variety of medications that could reduce the effectiveness of the cancer treatment or increase its toxic side effects, according to research” View full resource at foxnews.com
Most Recently Shared on March 16, 2012 at 12:43 pm By:
Common medicines may cut cancer drug potency: Many patients taking a widely prescribed class of oral cancer drug... http://t.co/Gwl2NyE7
Common medicines may cut cancer drug potency: study | Reuters
reuters.com — “(Reuters) - Many patients taking a widely prescribed class of oral cancer drugs are also using a variety of medications that could reduce the effectiveness of the cancer treatment or increase its toxic” View full resource at reuters.com
Most Recently Shared on March 16, 2012 at 12:02 pm By:
Common medicines may cut cancer drug potency: study: (Reuters) - Many patients taking a widely pre... http://t.co/3mv5Ufhd #health #news
Common medicines may cut cancer drug potency: study - Yahoo! News
news.yahoo.com — “From Yahoo! News: (Reuters) - Many patients taking a widely prescribed class of oral cancer drugs are also using a variety of medications that could reduce the effectiveness of the cancer treatment or increase its toxic side effects, according to research by Medco Health Solutions Inc. For example, 43 percent of patients taking the highly effective leukemia drug Gleevec were also on another medicine that could diminish its efficacy, while 68 percent were taking something that could potentially r” View full resource at news.yahoo.com
Most Recently Shared on March 16, 2012 at 5:25 am By:
Kidney Cancer Health Executive
Common medicines may cut kidney cancer drug potency http://t.co/SOyaBzlK
Common medicines may cut cancer drug potency: study - Yahoo! News
news.yahoo.com — “From Yahoo! News: (Reuters) - Many patients taking a widely prescribed class of oral cancer drugs are also using a variety of medications that could reduce the effectiveness of the cancer treatment or increase its toxic side effects, according to research by Medco Health Solutions Inc. For example, 43 percent of patients taking the highly effective leukemia drug Gleevec were also on another medicine that could diminish its efficacy, while 68 percent were taking something that could potentially r” View full resource at news.yahoo.com
Most Recently Shared on March 16, 2012 at 5:21 am By:
Common medicines may cut cancer drug potency: study: (Reuters) - Many patients taking a widely prescribed class ... http://t.co/6gY7a0Gg
Studies underscore genetic complexity of head and neck squamous cell cancers | Oral Cancer News
oralcancernews.org — “Studies underscore genetic complexity of head and neck squamous cell cancers | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on March 15, 2012 at 3:57 pm By:
Rhei granted marketing approval for MuGard in China
news-medical.net — “ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.” View full resource at news-medical.net
Most Recently Shared on February 24, 2012 at 5:37 pm By:
Ovarian Cancer News: Rhei granted marketing approval for MuGard in China: ACCESS PHARMACEUTICALS, INC., a biopha... http://t.co/MZw6kyPE
Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer
news-medical.net — “Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.” View full resource at news-medical.net
Most Recently Shared on January 5, 2012 at 10:28 am By:
Meningitis News: Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer: Viamet Pharma... http://t.co/RLiZ4zPY
FDA Approves Cetuximab for Late-Stage Head and Neck Cancer | Oral Cancer News
oralcancernews.org — “FDA Approves Cetuximab for Late-Stage Head and Neck Cancer | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 9, 2011 at 1:05 pm By:
US FDA approval for expanded use of Erbitux | Oral Cancer News
oralcancernews.org — “US FDA approval for expanded use of Erbitux | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 9, 2011 at 8:24 am By:
FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News
oralcancernews.org — “FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 8, 2011 at 2:00 pm By:
ADA updates guidelines for managing ONJ risk patients | Oral Cancer News
oralcancernews.org — “ADA updates guidelines for managing ONJ risk patients | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 6, 2011 at 12:10 pm By:
GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy | Oral Cancer News
oralcancernews.org — “GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on October 15, 2011 at 9:06 am By:
Tarceva (erlotinib) Good Alternative To Chemotherapy For Some Lung Cancer Patients, UK
medicalnewstoday.com — “According to today's announcement by Roche, Tarceva (erlotinib), an oral lung cancer treatment, has been officially licensed as first-line monotherapy for the treatment of patients with advanced” View full resource at medicalnewstoday.com
Most Recently Shared on September 11, 2011 at 4:43 am By:
MedicalNewsToday: Tarceva (erlotinib) Good Alternative To Chemotherapy For Some Lung Cancer: http://t.co/sv66ODD Full http://t.co/NqqVsQf
Cancer drug resistance strategy uncovered | Oral Cancer News
oralcancernews.org — “Cancer drug resistance strategy uncovered | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on September 9, 2011 at 3:20 pm By:
Advertisement
